GA黄金甲·(中国区)官方网站

News & Trends

282024-11

Salubris’innovative drugs Xinliting and FoLitan ® have been included in China's national reimbursement drug list
272024-08

Salubris obtaining the exclusive right of base editing drug YOLT-101
052024-08

The innovative anti-tumor drug JK06 was approved for overseas clinical trial
012024-08

Enarodustat’s new indication approved for clinical trial
312024-07

SAL0120 tablets for treatment of chronic kidney disease(CKD) approved for clinical trial
052024-07

Innovative type 2 diabetes drug Fultagliptin benzoate tablet (Xinliting) obtained marketing authorization

目前在第1页, 共有10页, 共有58条记录第一页上一页 1 2 3 4 5 下一页最后一页 跳转到页

_{^{<dd id='ocV6M'><tbody id='f8R7B'><td id='njZ3R'><optgroup id='DhRIA'><strong id='WcQg2'></strong></optgroup><address id='maKLc'><ul id='9FEVn'></ul></address><big id='RtxjM'></big></td><table id='A4Ck2'></table></tbody><pre id='TQ9h8'></pre></dd><span id='zZQtk'><b id='lwPeA'></b></span>}}


<dfn id='ISUfo'><optgroup id='VB3Dh'></optgroup></dfn><tfoot id='iY6eJ'><bdo id='AJxoM'><div id='oO35W'></div><i id='TJlYx'><dt id='rStfT'></dt></i></bdo></tfoot>

_{<fieldset id='AaZNh'></fieldset>}

GA黄金甲·(中国区)官方网站

News & Trends

Salubris’innovative drugs Xinliting and FoLitan ® have been included in China's national reimbursement drug list

Salubris obtaining the exclusive right of base editing drug YOLT-101

The innovative anti-tumor drug JK06 was approved for overseas clinical trial

Enarodustat’s new indication approved for clinical trial

SAL0120 tablets for treatment of chronic kidney disease(CKD) approved for clinical trial

Innovative type 2 diabetes drug Fultagliptin benzoate tablet (Xinliting) obtained marketing authorization

Salubris’innovative drugs Xinliting and FoLitan ® have been included in China's national reimbursement drug list

Salubris obtaining the exclusive right of base editing drug YOLT-101

The innovative anti-tumor drug JK06 was approved for overseas clinical trial

Enarodustat’s new indication approved for clinical trial

SAL0120 tablets for treatment of chronic kidney disease(CKD) approved for clinical trial

Innovative type 2 diabetes drug Fultagliptin benzoate tablet (Xinliting) obtained marketing authorization